Neuren Pharmaceuticals (ASX:NEU) Share Price and News

Market Cap (19-Sep) $1,574,532,736 (454th)	Close (30-Jun) $12.25 0 (0%)	Volume (30-Jun) 261,029	Shortsold (26-May) 7,938,725 (6.28%) (46th)
52w High $22.99	52w Low $11.00	P/E 51.02	EPS 0.23

	Subject
	NEU NEU Ann: Neuren completes enrolment in Phelan-McDermid Phase 2 trial
	1 (current) 2 3
	NEU NEU Ann: Neuren opens first site in US for Prader-Willi Phase 2 trial
	NEU NEU Ann: Change of Director's Interest Notice
	NEU NEU Ann: Neuren receives US$40m milestone payment
	NEU NEU Ann: Neuren presenting at Jefferies Global Healthcare Conference
	NEU NEU Ann: Results of Meeting
	NEU NEU Ann: AGM Chair Address & CEO Presentation
	NEU NEU Ann: Notice of Annual General Meeting/Proxy Form
	NEU NEU Ann: Virtual AGM online guide
	NEU NEU Ann: Q1 2023 quarterly activity and cash flow report
	NEU NEU Ann: Appendix 4G
	NEU NEU Ann: 2022 Annual Report to shareholders
	NEU NEU Ann: DAYBUE (trofinetide) launched in US - Neuren earns US$40m
	NEU NEU Ann: Application for quotation of securities - NEU
	NEU NEU Ann: Investor Presentation, 14 March 2023
	NEU NEU Ann: Notification of investor webinar
	NEU NEU Ann: FDA approves Daybue - the first treatment for Rett syndrome
	NEU NEU Ann: Initial Director's Interest Notice
	NEU NEU Ann: Neuren appoints Joe Basile to board of directors
	NEU NEU Ann: Investor presentation, 1 March 2023
	NEU NEU Ann: Investor Presentation, 24 February 2023
	NEU NEU Ann: Neuren reports 2022 full-year results
	NEU NEU Ann: Appendix 4E and 2022 full year accounts
	NEU NEU Ann: Application for quotation of securities - NEU
	NEU NEU Ann: Q4 2022 quarterly activity and cash flow report
	NEU NEU Ann: Prader-Willi syndrome IND for NNZ-2591 approved by FDA
	NEU NEU Ann: Neuren submits IND & first patients complete Phase 2 trials
	NEU NEU Ann: Becoming a substantial holder
	NEU NEU Ann: Ceasing to be a substantial holder
	NEU NEU Ann: Change in substantial holding
	NEU NEU Ann: Jefferies London Healthcare Conference 2022 presentation
	NEU NEU Ann: Q3 2022 quarterly activity and cash flow report
	NEU NEU Ann: Neuren receives US$10 million milestone payment
	NEU NEU Ann: Investor presentation, 14 September 2022
	NEU NEU Ann: Rett Syndrome NDA accepted for Priority Review by FDA
	NEU NEU Ann: S&P DJI Announces September 2022 Quarterly Rebalance
	NEU NEU Ann: Half-year shareholder update
	NEU NEU Ann: Half Yearly Report and Accounts
	NEU NEU Ann: Investor presentation, 8 August 2022
	NEU NEU Ann: Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHS
	NEU NEU Ann: Quarterly Activities/Appendix 4C Cash Flow Report
	NEU NEU Ann: Acadia submits Rett Syndrome New Drug Application to the FDA
	NEU NEU Ann: Neuren commences Phase 2 trial of NNZ-2591 in Angelman
	NEU NEU Ann: Notification regarding unquoted securities - NEU
	NEU NEU Ann: Neuren appoints Chief Medical Officer in United States
	NEU NEU Ann: Results of Meeting
	NEU NEU Ann: AGM Chairman's Address & CEO Presentation
	NEU NEU Ann: Quarterly Activities/Appendix 4C Cash Flow Report
	NEU NEU Ann: Virtual AGM online guide
	NEU NEU Ann: Notice of Annual General Meeting/Proxy Form

Similar Companies

Cann Group

CAN

Creso Pharma

CPH

Ecofibre

EOF

Incannex Healthcare

IHL

Medical Developments International

MVP

Mayne Pharma Group

MYX

Probiotec

PBP

Recce Pharmaceuticals Ltd

RCE

Starpharma Holdings

SPL

End of Day Prices

Date	Close	Volume	Change
18-Sep	$20.14	996,599	+0.87 (4.51%)
12-Sep	$19.27	721,746	+0.67 (3.60%)
11-Sep	$18.60	1,200,631	-1.88 (9.18%)
05-Sep	$20.48	718,139	+0.50 (2.50%)
04-Sep	$19.98	1,139,389	+0.98 (5.16%)
03-Sep	$19.00	728,440	-0.01 (0.05%)
29-Aug	$19.01	859,689	-0.50 (2.56%)
28-Aug	$19.51	842,666	+2.34 (13.63%)
22-Aug	$17.17	294,857	-0.16 (0.92%)
21-Aug	$17.33	294,217	+0.98 (5.99%)
15-Aug	$16.35	534,147	-0.19 (1.15%)
14-Aug	$16.54	773,667	-1.01 (5.75%)
07-Aug	$17.55	962,321	+0.26 (1.50%)
31-Jul	$17.29	529,813	+0.66 (3.97%)
30-Jul	$16.63	240,750	-0.07 (0.42%)
8 up, 7 down, and 0 flat days

High $12.50	Low $12.07	Trades 2,722	Turnover $3,205,258	Volume 261,029
30 June 2023 at 4:55pm

High $12.50	Low $12.07	Trades 2,722	Turnover $3,205,258	Volume 261,029
30 June 2023 at 4:55pm

Neuren Pharmaceuticals Health Care

$12.25 -0.23 (-1.84%)

$12.25 -0.23 (-1.84%)

Followers

Prices

Announcements

Similar Companies

End of Day Prices